Latest News for: gri

Edit

Sustainability report (Zug Estates Sustainability Report GRI standards 2025) (Zug Estates Holding AG)

Public Technologies 19 Feb 2026
GRI Index 68 ... GRI 2-6 ... The requirements of the GRI Standards, UN Development Goals and ESG rating agencies were also taken into account ... GRI 3-1 ... GRI 3-2 ... ‌GRI 2-29. GRI 2-13 ... ‌GRI 2-14. GRI 2-17 ... GRI 2-12 ... GRI 201-1 ... GRI 201-2.
Edit

GRI has released guidelines for the application of the new standard GRI 101: Biodiversity 2024

AK&M Information Agency 17 Feb 2026
Link to source to read story ....
Edit

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Nasdaq Globe Newswire 17 Feb 2026
Access the “What This Means” segment here ... .
Edit

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Nasdaq Globe Newswire 05 Feb 2026
– Live video webcast on Wednesday, February 11th at 1.00 PM EST ... .
Edit

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Nasdaq Globe Newswire 04 Feb 2026
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026� ... .
Edit

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights (Form 8-K) (Gri Bio Inc)

Public Technologies 04 Feb 2026
GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Edit

2025 Global Reporting Initiative (GRI) (Hillenbrand Inc)

Public Technologies 04 Feb 2026
GRI Standard ... GRI 2 ... GLOBAL REPORTING INITIATIVE (GRI). Hillenbrand has reported the information cited in this GRI content index for the period 1 October 2024 - 30 September 2025 with reference to the GRI Standards ... GRI 3 ... GRI 201 ... GRI 205 ... GRI 206 ... GRI 207.
Edit

Notice of Effectiveness (Form EFFECT) (Gri Bio Inc)

Public Technologies 02 Feb 2026
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 ... GRI Bio, Inc ... Gri Bio Inc.
Edit

Material Agreement (Form 8-K) (Gri Bio Inc)

Public Technologies 30 Jan 2026
) Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on May 20, 2024, GRI Bio, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C ... Disclaimer. Gri Bio Inc.
Edit

Supplemental Prospectus (Form 424B5) (Gri Bio Inc)

Public Technologies 30 Jan 2026
). Filed pursuant to Rule 424(b)(5). Registration No. 333-279348. PROSPECTUS SUPPLEMENT ... GRI BIO, INC. Up to $60,000,000. Common Stock ... Our Common Stock is listed on the Nasdaq Capital Market under the symbol "GRI" ... H.C ... Disclaimer. Gri Bio Inc.
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (Gri Bio Inc)

Public Technologies 30 Jan 2026
GRI BIO, INC ... Amended and Restated GRI Bio, Inc ... GRI Bio, Inc ... (the "Registrant"), reserved for issuance pursuant to the Amended and Restated GRI Bio, Inc ... 99.1# Amended and Restated GRI Bio, Inc ... GRI BIO, INC ... Gri Bio Inc.
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (Gri Bio Inc)

Public Technologies 30 Jan 2026
Our product candidate, GRI-0621, is an oral inhibitor of type 1 iNKT cells ... We most recently evaluated GRI-0621 in a randomized, double-blind, multi-center, 2-arm Phase 2a clinical trial for the treatment of patients diagnosed with IPF ... Gri Bio Inc.
Edit

Registration Statement - Specified Transactions (Form S-3) (Gri Bio Inc)

Public Technologies 30 Jan 2026
GRI BIO, INC ... GRI Bio, Inc ... Our common stock is listed on The Nasdaq Capital Market under the symbol "GRI." On January 26, 2026, the last reported sale price of our common stock was $5.55 per share ... About GRI Bio, Inc ... GRI BIO, INC ... Gri Bio Inc.
Edit

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers ...

Nasdaq Globe Newswire 28 Jan 2026
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy ... .
Edit

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF (Form 8-K) (Gri Bio Inc)

Public Technologies 28 Jan 2026
GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...

Article Search

tools
×
×
×
×